NeuroMetrix Reports Q3 2022 Financial Results
WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq:NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company’s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.
Related news for (NURO)
- electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
- electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
- NeuroMetrix to be Acquired by electroCore
- NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
- NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)